Skip to main content
Top
Published in: BMC Public Health 1/2014

Open Access 01-12-2014 | Study protocol

A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling

Authors: Ruth Zimmermann, Ulrich Marcus, Dirk Schäffer, Astrid Leicht, Benjamin Wenz, Stine Nielsen, Claudia Santos-Hövener, R Stefan Ross, Oumaima Stambouli, Boris-Alexander Ratsch, Norbert Bannert, Claus-Thomas Bock, Claudia Kücherer, Osamah Hamouda

Published in: BMC Public Health | Issue 1/2014

Login to get access

Abstract

Background

People who inject drugs are at high risk for hepatitis B, hepatitis C and HIV. HTLV was reported by neighboring countries to be prevalent in this population, but the situation for Germany is unclear. To generate seroprevalence and related behavioural data and to enhance prevention efforts against these infections for drug users in Germany, a multicentre sero- and behavioural survey was initiated. People who inject drugs are not well reached by services for testing and counselling for blood-borne infections in Germany. An interventional part of the study is intended to prove feasibility and acceptance of testing and counselling in low-threshold drop-in settings.

Methods/Design

Between May 2011 and March 2015, eligible participants (persons having injected drugs within the last 12 months, aged 16 years+, and living in the study city) are recruited by respondent driven sampling, using low-threshold drop-in facilities as study-sites in eight German cities with large drug scenes. Calculated sample size is 2,033 participants. Capillary blood samples collected as dried blood spots are anonymously tested for serological and molecular markers of hepatitis B and C, HIV, and HTLV I and II. A detailed face-to-face-interview about hepatitis- and HIV-related knowledge, former testing, imprisonment, sexual and injecting risk behaviour is conducted with participants. Staff is trained to offer pre- and post-test-counselling of blood-borne infections and HIV rapid testing to participants.

Discussion

We chose respondent driven sampling for recruitment of participants to improve representativeness of results. Persons, who are not reached by the facility where the study is conducted, are aimed to be included by recruitment through their personal social network of injecting drug users. To reduce differential biases in the questions on knowledge of transmission and prevention of infections, we present true statements on hepatitis B, C and HIV, their possible routes of transmission and measures of prevention to participants. Participants are told that the statements are true and are asked to answer if they knew this fact already or if it is new to them. In case of knowledge gaps they are offered free targeted counselling as well as free HIV rapid testing and post-test counselling of HIV and hepatitis test results.
Appendix
Available only for authorised users
Literature
2.
go back to reference Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011, 378 (9791): 571-583. 10.1016/S0140-6736(11)61097-0.CrossRefPubMedPubMedCentral Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011, 378 (9791): 571-583. 10.1016/S0140-6736(11)61097-0.CrossRefPubMedPubMedCentral
3.
go back to reference Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, Thamm M: Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013, 56 (5–6): 707-715.CrossRefPubMed Poethko-Muller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, Thamm M: Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2013, 56 (5–6): 707-715.CrossRefPubMed
4.
go back to reference Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I: History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol. 1997, 26 (6): 1359-1366. 10.1093/ije/26.6.1359.CrossRefPubMed Stark K, Bienzle U, Vonk R, Guggenmoos-Holzmann I: History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol. 1997, 26 (6): 1359-1366. 10.1093/ije/26.6.1359.CrossRefPubMed
5.
go back to reference Brack J: Die Hepatitiden B und C bei drogenabhängigen Patienten: Eine epidemiologische Studie. Suchttherapie. 2002, 2002 (3 Suppl 1): 3-10.CrossRef Brack J: Die Hepatitiden B und C bei drogenabhängigen Patienten: Eine epidemiologische Studie. Suchttherapie. 2002, 2002 (3 Suppl 1): 3-10.CrossRef
6.
go back to reference Williams R: Global challenges in liver disease. Hepatology. 2006, 44 (3): 521-526. 10.1002/hep.21347.CrossRefPubMed Williams R: Global challenges in liver disease. Hepatology. 2006, 44 (3): 521-526. 10.1002/hep.21347.CrossRefPubMed
7.
go back to reference Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005, 5 (9): 558-567. 10.1016/S1473-3099(05)70216-4.CrossRefPubMed Shepard CW, Finelli L, Alter MJ: Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005, 5 (9): 558-567. 10.1016/S1473-3099(05)70216-4.CrossRefPubMed
8.
go back to reference Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ: Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007, 28 (5): 519-524. 10.1086/513727.CrossRefPubMed Kamili S, Krawczynski K, McCaustland K, Li X, Alter MJ: Infectivity of hepatitis C virus in plasma after drying and storing at room temperature. Infect Control Hosp Epidemiol. 2007, 28 (5): 519-524. 10.1086/513727.CrossRefPubMed
9.
go back to reference Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebesehl N, Wilhelm C, Steinmann J, Pietschmann T, Steinmann E: Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis. 2013, 207 (2): 281-287. 10.1093/infdis/jis677.CrossRefPubMed Doerrbecker J, Behrendt P, Mateu-Gelabert P, Ciesek S, Riebesehl N, Wilhelm C, Steinmann J, Pietschmann T, Steinmann E: Transmission of hepatitis C virus among people who inject drugs: viral stability and association with drug preparation equipment. J Infect Dis. 2013, 207 (2): 281-287. 10.1093/infdis/jis677.CrossRefPubMed
10.
go back to reference Doerrbecker J, Friesland M, Ciesek S, Erichsen TJ, Mateu-Gelabert P, Steinmann J, Steinmann J, Pietschmann T, Steinmann E: Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis. 2011, 204 (12): 1830-1838. 10.1093/infdis/jir535.CrossRefPubMedPubMedCentral Doerrbecker J, Friesland M, Ciesek S, Erichsen TJ, Mateu-Gelabert P, Steinmann J, Steinmann J, Pietschmann T, Steinmann E: Inactivation and survival of hepatitis C virus on inanimate surfaces. J Infect Dis. 2011, 204 (12): 1830-1838. 10.1093/infdis/jir535.CrossRefPubMedPubMedCentral
11.
go back to reference Paintsil E, He H, Peters C, Lindenbach BD, Heimer R: Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010, 202 (7): 984-990. 10.1086/656212.CrossRefPubMedPubMedCentral Paintsil E, He H, Peters C, Lindenbach BD, Heimer R: Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. J Infect Dis. 2010, 202 (7): 984-990. 10.1086/656212.CrossRefPubMedPubMedCentral
12.
go back to reference Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, Backmund M: Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol. 2007, 22 (1): 80-85. 10.1111/j.1440-1746.2006.04358.x.CrossRefPubMed Reimer J, Lorenzen J, Baetz B, Fischer B, Rehm J, Haasen C, Backmund M: Multiple viral hepatitis in injection drug users and associated risk factors. J Gastroenterol Hepatol. 2007, 22 (1): 80-85. 10.1111/j.1440-1746.2006.04358.x.CrossRefPubMed
13.
go back to reference Backmund M, Meyer K, Wächtler M, Eichenlaub D: Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol. 2003, 18 (6): 563-568.CrossRefPubMed Backmund M, Meyer K, Wächtler M, Eichenlaub D: Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol. 2003, 18 (6): 563-568.CrossRefPubMed
14.
go back to reference Thane K, Wickert C, Verthein U: Abschlussbericht: Szenebefragung in Deutschland 2008. 2009, Hamburg: Institut für interdisziplinäre Suchtforschung,- ISD Thane K, Wickert C, Verthein U: Abschlussbericht: Szenebefragung in Deutschland 2008. 2009, Hamburg: Institut für interdisziplinäre Suchtforschung,- ISD
15.
go back to reference Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect. 2002, 129: 577-585. 10.1017/S0950268802007902.CrossRefPubMedPubMedCentral Roy K, Hay G, Andragetti R, Taylor A, Goldberg D, Wiessing L: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect. 2002, 129: 577-585. 10.1017/S0950268802007902.CrossRefPubMedPubMedCentral
16.
go back to reference Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J: Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Eurosurveillance. 2011, 16 (48): 9-13. Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J: Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Eurosurveillance. 2011, 16 (48): 9-13.
17.
go back to reference Stark K, Schreier E, Müller R, Wirth D, Driesel G, Bienzle U: Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis. 1995, 27 (4): 331-337. 10.3109/00365549509032726.CrossRefPubMed Stark K, Schreier E, Müller R, Wirth D, Driesel G, Bienzle U: Prevalence and determinants of anti-HCV seropositivity and of HCV genotype among intravenous drug users in Berlin. Scand J Infect Dis. 1995, 27 (4): 331-337. 10.3109/00365549509032726.CrossRefPubMed
18.
go back to reference Robert Koch-Institut (RKI): Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis C im Jahr 2012. Epid Bull. 2013, 30: 273-284. Robert Koch-Institut (RKI): Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis C im Jahr 2012. Epid Bull. 2013, 30: 273-284.
19.
go back to reference Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M, Razafandratsima N, Emmanuelli J, Guibert G, Barin F: A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis. 2009, 9 (1): 113-10.1186/1471-2334-9-113.CrossRefPubMedPubMedCentral Jauffret-Roustide M, Le Strat Y, Couturier E, Thierry D, Rondy M, Quaglia M, Razafandratsima N, Emmanuelli J, Guibert G, Barin F: A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect Dis. 2009, 9 (1): 113-10.1186/1471-2334-9-113.CrossRefPubMedPubMedCentral
20.
go back to reference Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, Ncube F, Parry JV: Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat. 2011, 18 (4): 262-270. 10.1111/j.1365-2893.2010.01297.x.CrossRefPubMed Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, Ncube F, Parry JV: Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat. 2011, 18 (4): 262-270. 10.1111/j.1365-2893.2010.01297.x.CrossRefPubMed
21.
go back to reference Crofts N, Aitken CK: Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria in 1990–1995. Med J Aust. 1997, 167 (1): 17-20.PubMed Crofts N, Aitken CK: Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria in 1990–1995. Med J Aust. 1997, 167 (1): 17-20.PubMed
22.
go back to reference Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL: Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006, 101 (10): 1499-1508. 10.1111/j.1360-0443.2006.01543.x.CrossRefPubMed Maher L, Jalaludin B, Chant KG, Jayasuriya R, Sladden T, Kaldor JM, Sargent PL: Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction. 2006, 101 (10): 1499-1508. 10.1111/j.1360-0443.2006.01543.x.CrossRefPubMed
24.
go back to reference European Centre for Disease Prevention and Control, WHO Regional Office for Europe: HIV/AIDS Surveillance in Europe 2010. 2011, Stockholm: European Centre for Disease Prevention and Control (ECDC) European Centre for Disease Prevention and Control, WHO Regional Office for Europe: HIV/AIDS Surveillance in Europe 2010. 2011, Stockholm: European Centre for Disease Prevention and Control (ECDC)
25.
go back to reference Robert Koch-Institut: Weiterführende Analysen zur HIV-Inzidenz- und -Prävalenzschätzung 2012. Epidemiologisches Bulletin-Robert Koch Institut. 2013, 45: 1-12. Robert Koch-Institut: Weiterführende Analysen zur HIV-Inzidenz- und -Prävalenzschätzung 2012. Epidemiologisches Bulletin-Robert Koch Institut. 2013, 45: 1-12.
26.
go back to reference Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005, 24 (39): 6058-6068. 10.1038/sj.onc.1208968.CrossRefPubMed Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene. 2005, 24 (39): 6058-6068. 10.1038/sj.onc.1208968.CrossRefPubMed
27.
go back to reference Laperche S, Worms B, Pillonel J: Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang. 2009, 96 (2): 104-110. 10.1111/j.1423-0410.2008.01136.x.CrossRefPubMed Laperche S, Worms B, Pillonel J: Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang. 2009, 96 (2): 104-110. 10.1111/j.1423-0410.2008.01136.x.CrossRefPubMed
28.
go back to reference de la Fuente L, Toro C, Soriano V, Brugal MT, Vallejo F, Barrio G, Jimenez V, Silva T, Project Itinere Working Group: HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates. J Clin Virol. 2006, 35 (3): 244-249. 10.1016/j.jcv.2005.06.006.CrossRefPubMed de la Fuente L, Toro C, Soriano V, Brugal MT, Vallejo F, Barrio G, Jimenez V, Silva T, Project Itinere Working Group: HTLV infection among young injection and non-injection heroin users in Spain: prevalence and correlates. J Clin Virol. 2006, 35 (3): 244-249. 10.1016/j.jcv.2005.06.006.CrossRefPubMed
29.
go back to reference Abad M, Dronda F, Dominguez E, Moreno S, Vallejo A: HTLV-2b among HIV type 1-coinfected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2011, 27 (5): 579-583.PubMed Abad M, Dronda F, Dominguez E, Moreno S, Vallejo A: HTLV-2b among HIV type 1-coinfected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2011, 27 (5): 579-583.PubMed
30.
go back to reference Egan JF, O’Leary B, Lewis MJ, Mulcahy F, Sheehy N, Hasegawa H, Fitzpatrick F, O’Connor JJ, O’Riordan J, Hall WW: High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. AIDS Res Hum Retroviruses. 1999, 15 (8): 699-705. 10.1089/088922299310782.CrossRefPubMed Egan JF, O’Leary B, Lewis MJ, Mulcahy F, Sheehy N, Hasegawa H, Fitzpatrick F, O’Connor JJ, O’Riordan J, Hall WW: High rate of human T lymphotropic virus type IIa infection in HIV type 1-infected intravenous drug abusers in Ireland. AIDS Res Hum Retroviruses. 1999, 15 (8): 699-705. 10.1089/088922299310782.CrossRefPubMed
31.
go back to reference Silva AF, Almeida C, Martins HC, Coutinho R, Leitao E, Silva R, Paixao MT, Padua E: Prevalence and molecular characterization of human T cell leukemia virus type 2 in a group of intravenous drug users coinfected with HIV type 1 in Portugal. AIDS Res Hum Retroviruses. 2005, 21 (4): 249-255. 10.1089/aid.2005.21.249.CrossRefPubMed Silva AF, Almeida C, Martins HC, Coutinho R, Leitao E, Silva R, Paixao MT, Padua E: Prevalence and molecular characterization of human T cell leukemia virus type 2 in a group of intravenous drug users coinfected with HIV type 1 in Portugal. AIDS Res Hum Retroviruses. 2005, 21 (4): 249-255. 10.1089/aid.2005.21.249.CrossRefPubMed
32.
go back to reference Malm K, Ekermo B, Hillgren K, Britton S, Fredlund H, Andersson S: Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden. Scand J Infect Dis. 2012, 44 (11): 852-859. 10.3109/00365548.2012.689847.CrossRefPubMed Malm K, Ekermo B, Hillgren K, Britton S, Fredlund H, Andersson S: Prevalence of human T-lymphotropic virus type 1 and 2 infection in Sweden. Scand J Infect Dis. 2012, 44 (11): 852-859. 10.3109/00365548.2012.689847.CrossRefPubMed
33.
go back to reference Taylor GP, Bodeus M, Courtois F, Pauli G, Del Mistro A, Machuca A, Padua E, Andersson S, Goubau P, Chieco-Bianchi L, Soriano V, Coste J, Ades AE, Weber JN: The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr. 2005, 38 (1): 104-109. 10.1097/00126334-200501010-00018.CrossRefPubMed Taylor GP, Bodeus M, Courtois F, Pauli G, Del Mistro A, Machuca A, Padua E, Andersson S, Goubau P, Chieco-Bianchi L, Soriano V, Coste J, Ades AE, Weber JN: The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr. 2005, 38 (1): 104-109. 10.1097/00126334-200501010-00018.CrossRefPubMed
34.
go back to reference Ellerbrok H, Fleischer C, Vandamme AM, Kucherer C, Pauli G: Sequence analysis of two HTLV type I infections imported to Germany. AIDS Res Hum Retroviruses. 1997, 13 (14): 1255-1258. 10.1089/aid.1997.13.1255.CrossRefPubMed Ellerbrok H, Fleischer C, Vandamme AM, Kucherer C, Pauli G: Sequence analysis of two HTLV type I infections imported to Germany. AIDS Res Hum Retroviruses. 1997, 13 (14): 1255-1258. 10.1089/aid.1997.13.1255.CrossRefPubMed
35.
go back to reference European Centre for Disease Prevention and Control: HTLV-I/II transmission by tissue/cell transplantation. Part 1: epidemiological review. Technical Report. 2012, Stockholm: ECDC, 47- European Centre for Disease Prevention and Control: HTLV-I/II transmission by tissue/cell transplantation. Part 1: epidemiological review. Technical Report. 2012, Stockholm: ECDC, 47-
36.
go back to reference European Centre for Disease Prevention and Control: Evidence for the effectiveness of interventions to prevent infections among people who inject drugs; Part 1: needle and syringe programmes and other interventions for prevention hepatitis C, HIV and injecting risk behaviour. Technical Report. 2011, Stockholm: ECDC European Centre for Disease Prevention and Control: Evidence for the effectiveness of interventions to prevent infections among people who inject drugs; Part 1: needle and syringe programmes and other interventions for prevention hepatitis C, HIV and injecting risk behaviour. Technical Report. 2011, Stockholm: ECDC
37.
go back to reference European Centre for Disease Prevention and Control: Evidence for the effectiveness of interventions to prevent infections among people who inject drugs; Part 2: drug treatment for preventing hepatitis C, HIV and injecting risk behaviour. Technical Report. 2011, Stockholm: ECDC European Centre for Disease Prevention and Control: Evidence for the effectiveness of interventions to prevent infections among people who inject drugs; Part 2: drug treatment for preventing hepatitis C, HIV and injecting risk behaviour. Technical Report. 2011, Stockholm: ECDC
38.
go back to reference Wodak A, Cooney A: Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006, 41 (6–7): 777-813.CrossRefPubMed Wodak A, Cooney A: Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006, 41 (6–7): 777-813.CrossRefPubMed
39.
go back to reference Tilson H, Aramrattana A, Bozzette S, Celentano D, Falco M, Hammett T: PreventingHIV infection among injecting drug users in high-risk countries: an assessment of the evidence. 2006, Washington, D.C: National Academy of Sciences, Institute of Medicine Tilson H, Aramrattana A, Bozzette S, Celentano D, Falco M, Hammett T: PreventingHIV infection among injecting drug users in high-risk countries: an assessment of the evidence. 2006, Washington, D.C: National Academy of Sciences, Institute of Medicine
40.
go back to reference Verthein U, Haasen C, Reimer J: Switching from methadone to diamorphine: 2-year results of the german heroin-assisted treatment trial. Subst Use Misuse. 2011, 46 (8): 980-991. 10.3109/10826084.2010.540624.CrossRefPubMed Verthein U, Haasen C, Reimer J: Switching from methadone to diamorphine: 2-year results of the german heroin-assisted treatment trial. Subst Use Misuse. 2011, 46 (8): 980-991. 10.3109/10826084.2010.540624.CrossRefPubMed
41.
go back to reference UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance: Guidelines for Second Generation HIV Surveillance. 2000, Geneva: WHO UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance: Guidelines for Second Generation HIV Surveillance. 2000, Geneva: WHO
44.
go back to reference Wiessing L, Bravo MJ: 2013, Lisbon: EMCDDA, DRID guidance module: behavioural indicators for people who inject drugs, Version 1.0, 2013. Wiessing L, Bravo MJ: 2013, Lisbon: EMCDDA, DRID guidance module: behavioural indicators for people who inject drugs, Version 1.0, 2013.
45.
go back to reference Heckathorn DD: Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997, 44 (2): 174-199. 10.2307/3096941.CrossRef Heckathorn DD: Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl. 1997, 44 (2): 174-199. 10.2307/3096941.CrossRef
46.
go back to reference Magnani R, Sabin K, Saidel T, Heckathorn D: Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005, 19 (Suppl 2): S67-S72.CrossRefPubMed Magnani R, Sabin K, Saidel T, Heckathorn D: Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005, 19 (Suppl 2): S67-S72.CrossRefPubMed
47.
go back to reference Heckathorn DD: Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002, 49 (1): 11-34. 10.1525/sp.2002.49.1.11.CrossRef Heckathorn DD: Respondent-driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl. 2002, 49 (1): 11-34. 10.1525/sp.2002.49.1.11.CrossRef
48.
go back to reference Kraus L, Heppekausen K, Tretter F: Prävalenzschätzungen von Opiatkonsumenten in deutschen Großstädten: Methoden und Ergebnisse. SUCHT. 2004, 50 (1): 11-20.CrossRef Kraus L, Heppekausen K, Tretter F: Prävalenzschätzungen von Opiatkonsumenten in deutschen Großstädten: Methoden und Ergebnisse. SUCHT. 2004, 50 (1): 11-20.CrossRef
49.
go back to reference Johnston LG, Prybylski D, Raymond HF, Mirzazadeh A, Manopaiboon C, McFarland W: Incorporating the service multiplier method in respondent-driven sampling surveys to estimate the size of hidden and hard-to-reach populations: case studies from around the world. Sex Transm Dis. 2013, 40 (4): 304-310. 10.1097/OLQ.0b013e31827fd650.CrossRefPubMed Johnston LG, Prybylski D, Raymond HF, Mirzazadeh A, Manopaiboon C, McFarland W: Incorporating the service multiplier method in respondent-driven sampling surveys to estimate the size of hidden and hard-to-reach populations: case studies from around the world. Sex Transm Dis. 2013, 40 (4): 304-310. 10.1097/OLQ.0b013e31827fd650.CrossRefPubMed
50.
go back to reference Johnston L, Saumtally A, Corceal S, Mahadoo I, Oodally F: High HIV and hepatitis C prevalence amongst injecting drug users in Mauritius: findings from a population size estimation and respondent driven sampling survey. Int J Drug Policy. 2011, 22 (4): 252-258. 10.1016/j.drugpo.2011.05.007.CrossRefPubMed Johnston L, Saumtally A, Corceal S, Mahadoo I, Oodally F: High HIV and hepatitis C prevalence amongst injecting drug users in Mauritius: findings from a population size estimation and respondent driven sampling survey. Int J Drug Policy. 2011, 22 (4): 252-258. 10.1016/j.drugpo.2011.05.007.CrossRefPubMed
51.
go back to reference Sarrazin C, Berg T, Ross R, Schirmacher P, Wedemeyer H, Neumann U, Schmidt H, Spengler U, Wirth S, Kessler H: Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-infektion. Z Gastroenterol. 2010, 48: 289-351. 10.1055/s-0028-1110008.CrossRefPubMed Sarrazin C, Berg T, Ross R, Schirmacher P, Wedemeyer H, Neumann U, Schmidt H, Spengler U, Wirth S, Kessler H: Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-infektion. Z Gastroenterol. 2010, 48: 289-351. 10.1055/s-0028-1110008.CrossRefPubMed
52.
go back to reference Ross RS, Stambouli O, Gruner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M: Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots-performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J. 2013, 10 (72): 72-CrossRefPubMedPubMedCentral Ross RS, Stambouli O, Gruner N, Marcus U, Cai W, Zhang W, Zimmermann R, Roggendorf M: Detection of infections with hepatitis B virus, hepatitis C virus, and human immunodeficiency virus by analyses of dried blood spots-performance characteristics of the ARCHITECT system and two commercial assays for nucleic acid amplification. Virol J. 2013, 10 (72): 72-CrossRefPubMedPubMedCentral
53.
go back to reference Volz E, Wejnert C, Cameron S, Spiller M, Barash V, Degani I, Heckathorn DD: Respondent-Driven Sampling Analysis Tool (RDSAT) Version 7.1. 2012, Ithaca, NY: Cornell University Volz E, Wejnert C, Cameron S, Spiller M, Barash V, Degani I, Heckathorn DD: Respondent-Driven Sampling Analysis Tool (RDSAT) Version 7.1. 2012, Ithaca, NY: Cornell University
54.
go back to reference Prinzleve M, Müller O, Werse B, Bernard C: MoSyD Szenestudie - Die offene Drogenszene in Frankfurt am Main. 2004, Frankfurt am Main: Centre for Drug Research (CDR), 61- Prinzleve M, Müller O, Werse B, Bernard C: MoSyD Szenestudie - Die offene Drogenszene in Frankfurt am Main. 2004, Frankfurt am Main: Centre for Drug Research (CDR), 61-
55.
go back to reference Toan NL, le Song H, Kremsner PG, Duy DN, Binh VQ, Koeberlein B, Kaiser S, Kandolf R, Torresi J, Bock CT: Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology. 2006, 43 (6): 1375-1384. 10.1002/hep.21188.CrossRefPubMed Toan NL, le Song H, Kremsner PG, Duy DN, Binh VQ, Koeberlein B, Kaiser S, Kandolf R, Torresi J, Bock CT: Impact of the hepatitis B virus genotype and genotype mixtures on the course of liver disease in Vietnam. Hepatology. 2006, 43 (6): 1375-1384. 10.1002/hep.21188.CrossRefPubMed
56.
go back to reference Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, Schmidt HHJ, Spengler U, Wirth S, Kessler HH: Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion, AWMF-Register-Nr.: 021/012 (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.). Z Gastroenterol. 2010, 48: 289-351. 10.1055/s-0028-1110008.CrossRefPubMed Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U, Schmidt HHJ, Spengler U, Wirth S, Kessler HH: Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV)-Infektion, AWMF-Register-Nr.: 021/012 (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.). Z Gastroenterol. 2010, 48: 289-351. 10.1055/s-0028-1110008.CrossRefPubMed
57.
go back to reference Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger M: Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z Gastroenterol. 2011, 49: 871-930. 10.1055/s-0031-1273462.CrossRefPubMed Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S, Sarrazin C, Dollinger M: Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion. Z Gastroenterol. 2011, 49: 871-930. 10.1055/s-0031-1273462.CrossRefPubMed
58.
go back to reference Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011, 28 (10): 2731-2739. 10.1093/molbev/msr121.CrossRefPubMedPubMedCentral Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S: MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011, 28 (10): 2731-2739. 10.1093/molbev/msr121.CrossRefPubMedPubMedCentral
59.
go back to reference Bernard C, Werse B, Schell-Mack C: MoSyD Jahresbericht 2012 Drogentrends in Frankfurt am Main. 2013, Frankfurt am Main: Goethe Universität Frankfurt am Main, Centre For Drug Research (CDR) Bernard C, Werse B, Schell-Mack C: MoSyD Jahresbericht 2012 Drogentrends in Frankfurt am Main. 2013, Frankfurt am Main: Goethe Universität Frankfurt am Main, Centre For Drug Research (CDR)
60.
go back to reference Mills HL, Colijn C, Vickerman P, Leslie D, Hope V, Hickman M: Respondent driven sampling and community structure in a population of injecting drug users, Bristol UK. Drug Alcohol Depend. 2012, 126 (3): 324-332. 10.1016/j.drugalcdep.2012.05.036.CrossRefPubMed Mills HL, Colijn C, Vickerman P, Leslie D, Hope V, Hickman M: Respondent driven sampling and community structure in a population of injecting drug users, Bristol UK. Drug Alcohol Depend. 2012, 126 (3): 324-332. 10.1016/j.drugalcdep.2012.05.036.CrossRefPubMed
61.
go back to reference Malekinejad M, Johnston LG, Kendall C, Kerr LR, Rifkin MR, Rutherford GW: Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: a systematic review. AIDS Behav. 2008, 12 (4 Suppl): S105-S130.CrossRefPubMed Malekinejad M, Johnston LG, Kendall C, Kerr LR, Rifkin MR, Rutherford GW: Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: a systematic review. AIDS Behav. 2008, 12 (4 Suppl): S105-S130.CrossRefPubMed
Metadata
Title
A multicentre sero-behavioural survey for hepatitis B and C, HIV and HTLV among people who inject drugs in Germany using respondent driven sampling
Authors
Ruth Zimmermann
Ulrich Marcus
Dirk Schäffer
Astrid Leicht
Benjamin Wenz
Stine Nielsen
Claudia Santos-Hövener
R Stefan Ross
Oumaima Stambouli
Boris-Alexander Ratsch
Norbert Bannert
Claus-Thomas Bock
Claudia Kücherer
Osamah Hamouda
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2014
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-14-845

Other articles of this Issue 1/2014

BMC Public Health 1/2014 Go to the issue